Vericiguat
وریسیگوات
❤️ Cardiovascular SystemSoluble guanylate cyclase stimulator
Market / country: 🇺🇸 USA
Verquvo (US)
🧮 Dose calculator
Heart failure · Regimen source: FDA Verquvo · 2.1
- • With food. At risk of symptomatic hypotension: start 2.5 mg. Females of reproductive potential: pregnancy test before starting. FDA Verquvo · 2.1FDA Verquvo · 2.2
Enter age (weight is optional for this regimen).
🛡️ Safety & information
Contraindications
- ⛔ Concomitant other soluble guanylate cyclase stimulators (e.g. riociguat); pregnancy. FDA Verquvo · 4
Warnings
- • Boxed warning: embryo-fetal toxicity — exclude pregnancy before starting and use effective contraception until 1 month after stopping. FDA Verquvo · Boxed Warning
Important interactions
- • PDE5 inhibitors: not recommended (hypotension). FDA Verquvo · 7
Formulations
- 2.5 mg tablet — tablet 🇺🇸 USA FDA Verquvo · 3
- 5 mg tablet — tablet 🇺🇸 USA FDA Verquvo · 3
- 10 mg tablet — tablet 🇺🇸 USA FDA Verquvo · 3
👥 Special populations
- 🤰 PregnancyContraindicated
Label: contraindicated in pregnancy. FDA Verquvo · 4
“VERQUVO is contraindicated in pregnancy [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1) ].”
- 🤱 BreastfeedingDangerous / avoid
Label: breastfeeding not recommended, or choose between the drug and breastfeeding. FDA Verquvo · 8.2
“Because of the potential for serious adverse reactions in breastfed infants from VERQUVO, advise women not to breastfeed during treatment with VERQUVO.”
- 👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Verquvo · 8.4
“Safety and effectiveness of VERQUVO have not been established in pediatric patients.”
- 👴 Older adultsNo specific problem stated
Label: no specific difference or dose adjustment stated for older adults. FDA Verquvo · 8.5
“No dosage adjustment of VERQUVO is required in geriatric patients.”
- ⚥ Females & males of reproductive potentialUse with caution
Label has advice on pregnancy testing, contraception or fertility for females and males. FDA Verquvo · 8.3
“Contraception Females VERQUVO may cause fetal harm when administered to a pregnant woman.”
🔗 Reference links
- FDA (approval record)NDA214377
- DailyMed (FDA label)FDA Verquvo
- MedlinePlus (NIH)Vericiguat
- WHO ATC/DDDC01DX22
- Darooyab (Iran)Vericiguat
🇮🇷 Registered in Iran Darooyab · G-5577/Vericiguat
Dosage forms with Iranian generic codes, per Darooyab.
- 53611 · VERICIGUAT 2.5 mg TABLET · قرص وریسیگوات 2.5 میلی گرم
- 53612 · VERICIGUAT 5 mg TABLET · قرص وریسیگوات 5 میلی گرم
- 53613 · VERICIGUAT 10 mg TABLET · قرص وریسیگوات 10 میلی گرم
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Verquvo · 3FDA Verquvo · 2.1FDA Verquvo · 2.2FDA Verquvo · 4FDA Verquvo · Boxed WarningFDA Verquvo · 7FDA Verquvo · SPL approval / marketing categoryFDA Verquvo · 8.2FDA Verquvo · 8.4FDA Verquvo · 8.5FDA Verquvo · 8.3
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-5577/Vericiguat
- Clinical review⚠ Unverified